ondasdechoque.org
PT-BR

Greater trochanteric pain / gluteal tendinopathy · Randomized trial · 2022

Does a stronger course of shockwave help outer hip pain more than a minimal dose?

In this trial, average hip pain fell from about 6.7 to about 4.6 out of 10 over six months with three sessions of radial shockwave, one a week, at the strongest comfortable level, plus home exercises. A group given a minimal dose with the same exercises improved about as much, from about 6.1 to 4.

Similar to a minimal shockwave dose
adults with long-lasting outer hip pain
120
sessions, one a week
3
months of follow-up
6

Good to know: Both groups had shockwave and the same home exercises, so the trial compared two doses rather than shockwave with none.

Wheeler PC, Dudson C, Calver R, et al. Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine, 2022 · Read the paper ↗

How this study worked

Stronger dose +exercises57 peopleMinimal dose +exercises63 people
People were assigned to the groups by lot. Each dot is one person.

Conceptual animation: a radial wave spreads from the applicator and weakens with distance. Not to scale. Tap the field to send a pulse.

What happened

Average hip pain

0–10 pain scale · start, then 6 weeks to 6 months after the last session

Stronger dose + exercisesMinimal dose + exercises

Pain eased in both groups and stayed lower: from about 6.7 to 4.6 with the stronger dose, and from about 6.1 to 4 with the minimal dose, at six months.
Show the numbers
GroupStart6 weeks3 months6 months
Stronger dose + exercises6.754.74.6
Minimal dose + exercises6.14.54.44

The treatment

Stronger dose + exercises

Radial, once a week for 3 weeks

Radial wavesSpread out from the skin; strongest near the surface
Sessions
3, one a week
Pulses
2,000 per session
Strength
2.3–3.3bar strongest comfortable level; averages of 2.3, 2.8 and 3.3 bar in sessions 1–3 · 20 per second
Numbing
Not mentioned
Device
Intelect RPW (DJO Global Chattanooga)
Everyone also got
Daily home exercises: stretching, hip strengthening and balance

Minimal dose + exercises

Radial, once a week for 3 weeks

Radial wavesSpread out from the skin; strongest near the surface
Sessions
3, one a week
Pulses
500 per session
Strength
1.4bar the machine's lowest practical setting · 20 per second
Numbing
Not mentioned
Device
Intelect RPW (DJO Global Chattanooga)
Everyone also got
Daily home exercises: stretching, hip strengthening and balance

Compared with: A minimal dose of radial shockwave (500 pulses at the lowest practical setting), with the same home exercises

Settings are what each study used, not a prescription.

Who took part

120 adults (average age about 61, 82% women) with outer hip pain for at least six months despite rehabilitation, at one NHS sports medicine clinic.

hollow squares: no final score

Stronger dose + exercises55 of 57 measured
Minimal dose + exercises62 of 63 measured
117 of 120 people (98%) had a final score.

Side effects

Two people in each group had minor bruising. One person who was very sensitive to touch stopped after the first session because it hurt. No serious problems, such as tendon tears, were reported.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

Adults older than 18 with at least six months of imaging-confirmed greater trochanteric pain syndrome and insufficient response to at least three months of structured rehabilitation; 120 randomized in one NHS secondary-care sports medicine clinic. Mean age 60.6±11.5 years, 82% female, mean symptom duration 45.4±33.4 months.

Recommended/maximally tolerated radial ESWT57randomized

CONSORT: allocated n=57, of whom 56 received the allocated intervention; the other, a participant with marked touch hypersensitivity, withdrew after the first of the three sessions because of procedure pain (Figure 1 and Results agree); one additional participant later withdrew; 55/57 supplied 6-month data. This conflicts with abstract wording that allocation was equal.

Minimal-dose radial ESWT63randomized

CONSORT: allocated and treated n=63; one later lost/withdrew; 62/63 supplied 6-month data. This conflicts with abstract wording that allocation was equal.

Average self-reported pain3 reported outcomes
01
6 weeks

Average self-reported pain

Numerical Rating Scale (NRS) points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
5
Minimal-dose radial ESWT
4.5
010 points
Average self-reported pain · 6 weeks · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT556.7 (SD 1.5)5 (SD 2.4)
Minimal-dose radial ESWT626.1 (SD 1.8)4.5 (SD 2.4)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD): recommended-dose 6.7 (1.5) at baseline to 5 (2.4); minimal-dose 6.1 (1.8) to 4.5 (2.4). Time-by-group interaction p=0.959; within-group changes versus baseline were marked *** in both arms. This is no evidence of an additional benefit from the higher-dose schedule; the contrast is not an equivalence test.

Analysis details and source

Primary outcome specified as between-group change in average pain from baseline to six months. Two-way repeated-measures ANOVA interaction p-value; no treatment-effect estimate or confidence interval reported. Within-group significance does not establish comparative superiority.

02
3 months

Average self-reported pain

Numerical Rating Scale (NRS) points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
4.7
Minimal-dose radial ESWT
4.4
010 points
Average self-reported pain · 3 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT556.7 (SD 1.5)4.7 (SD 2.6)
Minimal-dose radial ESWT606.1 (SD 1.8)4.4 (SD 2.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD): recommended-dose 6.7 (1.5) at baseline to 4.7 (2.6); minimal-dose 6.1 (1.8) to 4.4 (2.7). Time-by-group interaction p=0.686; within-group changes versus baseline were marked *** in both arms. This is no evidence of an additional benefit from the higher-dose schedule; the contrast is not an equivalence test.

Analysis details and source

Primary outcome specified as between-group change in average pain from baseline to six months. Two-way repeated-measures ANOVA interaction p-value; no treatment-effect estimate or confidence interval reported. Within-group significance does not establish comparative superiority.

03
6 months

Average self-reported pain

Numerical Rating Scale (NRS) points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
4.6
Minimal-dose radial ESWT
4
010 points
Average self-reported pain · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT556.7 (SD 1.5)4.6 (SD 2.8)
Minimal-dose radial ESWT626.1 (SD 1.8)4 (SD 2.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD): recommended-dose 6.7 (1.5) at baseline to 4.6 (2.8); minimal-dose 6.1 (1.8) to 4 (2.7). Time-by-group interaction p=0.841; within-group changes versus baseline were marked *** in both arms. This is no evidence of an additional benefit from the higher-dose schedule; the contrast is not an equivalence test.

Analysis details and source

Primary outcome specified as between-group change in average pain from baseline to six months. Two-way repeated-measures ANOVA interaction p-value; no treatment-effect estimate or confidence interval reported. Within-group significance does not establish comparative superiority.

Worst pain, stiffness, and hip-specific function1 reported outcome
04
Baseline, 6 weeks, 3 months, and 6 months

Worst pain, stiffness, and hip-specific function

NRS; VISA-G; NAHS; OHS mean ± SD

worst pain: Recommended-dose: baseline 8 ± 1.4; 6 weeks 6.9 ± 2.4; 3 months 6.2 ± 2.5; 6 months 6 ± 2.8; Minimal-dose: baseline 7.9 ± 1.6; 6 weeks 5.9 ± 2.7; 3 months 6 ± 2.7; 6 months 5.5 ± 3.1; time×group interaction p at 6 weeks / 3 months / 6 months = 0.115 / 0.933 / 0.490; within-arm significance: ** or *** at all follow-ups in both groups. average stiffness: Recommended-dose: baseline 5 ± 2.7; 6 weeks 4.1 ± 2.6; 3 months 3.7 ± 2.6; 6 months 4 ± 2.8; Minimal-dose: baseline 4.8 ± 2.8; 6 weeks 3.6 ± 2.7; 3 months 3.4 ± 2.5; 6 months 3.5 ± 2.7; time×group interaction p at 6 weeks / 3 months / 6 months = 0.611 / 0.890 / 0.621; within-arm significance: ** or *** at all follow-ups in both groups. VISA-G: Recommended-dose: baseline 45 ± 18; 6 weeks 53 ± 17; 3 months 55 ± 20; 6 months 55 ± 22; Minimal-dose: baseline 50 ± 16; 6 weeks 57 ± 19; 3 months 61 ± 19; 6 months 62 ± 20; time×group interaction p at 6 weeks / 3 months / 6 months = 0.760 / 0.940 / 0.771; within-arm significance: ** in intervention at all visits; control * at 6 weeks, *** at months 3 and 6. NAHS total: Recommended-dose: baseline 43.6 ± 12.9; 6 weeks 46.9 ± 13.2; 3 months 51.2 ± 14.2; 6 months 49.9 ± 15.4; Minimal-dose: baseline 42.6 ± 11.9; 6 weeks 50.3 ± 16.5; 3 months 54.2 ± 13.7; 6 months 54.6 ± 16.1; time×group interaction p at 6 weeks / 3 months / 6 months = 0.214 / 0.247 / 0.118; within-arm significance: * at 6 weeks, ** at months 3 and 6 in intervention; ** then *** in control. OHS: Recommended-dose: baseline 25.1 ± 8.1; 6 weeks 27.9 ± 8.8; 3 months 30.8 ± 9.1; 6 months 29.9 ± 9.2; Minimal-dose: baseline 25.1 ± 7.9; 6 weeks 31.1 ± 9.8; 3 months 33 ± 9; 6 months 34.1 ± 9.2; time×group interaction p at 6 weeks / 3 months / 6 months = 0.162 / 0.336 / 0.065; within-arm significance: ** at all visits in intervention; *** at all visits in control.

Analysis details and source

All listed within-arm changes are secondary and do not imply a between-group effect. VISA-G range 0–100% higher better; NAHS 0–80 and OHS 0–48 higher better. The interaction p-values are reported separately at each follow-up.

Wider function, sleep, pain-processing, and mood measures1 reported outcome
05
Baseline, 6 weeks, 3 months, and 6 months

Wider function, sleep, pain-processing, and mood measures

painDETECT; CSI; ODI; EQ-5D; HADS; PHQ-4; GAD-7; PHQ-9; PSQI; Roles & Maudsley mean ± SD or percentage ± SD, as defined in Table 4

Means ± SD in the order baseline / 6 weeks / 3 months / 6 months (Table 4). painDETECT: recommended 12.4 → 10.4 → 9.5 → 9.8 (SD 7.0,5.7,5.7,6.2), minimal 10.8 → 9.2 → 8 → 8.7 (SD 7.4,6.4,5.8,6.8), interaction p .796/.939/.771; within-arm: recommended *, **, **; minimal none, *, *. CSI (%): recommended 33±16,30±16,27±15,28±17; minimal 31±15,30±16,25±15,26±17; p .626/.918/.983; both groups show within-arm improvement at all follow-ups (* to ***). ODI (%): recommended 39±17,35±18,30±19,32±20; minimal 34±14,28±17,27±17,25±17; p .551/.700/.656; within-arm improvement in both arms throughout (* to ***). EQ-5D self-rated health (%): recommended 67±17,71±17,70±20,66±23; minimal 70±17,70±18,69±22,75±15; p .503/.481/.187; only minimal group month-6 improvement marked *. HADS anxiety: recommended 6.1±3.8,5.3±3.8,4.6±3.8,4.5±3.8; minimal 5.4±3.7,5.0±3.7,4.0±3.5,4.5±4.1; p .685/.932/.544; within-arm improvement at all follow-ups in recommended, months 3 and 6 in minimal. HADS depression: recommended 5.3±3.3,5.1±4.0,4.0±3.5,3.9±3.5; minimal 4.9±3.7,4.3±3.8,3.8±3.3,3.9±3.6; p .660/.902/.646; improvement at months 3 and 6 in both. PHQ-4: recommended 1.8±2.1,1.7±2.1,1.2±2.2,1.5±2.2; minimal 1.6±2.4,1.7±2.5,1.2±2.0,1.5±2.1; p .670/.667/.665; no within-arm significance shown. GAD-7: recommended 4.1±3.8,3.6±3.7,2.8±3.7,3.2±3.8; minimal 3.8±4.3,3.7±4.2,2.7±3.2,3.4±4.2; p .760/.822/.651; only recommended at month 3 marked *. PHQ-9: recommended 5.4±4.6,5.6±5.3,4.3±4.9,4.7±4.8; minimal 5.2±4.8,4.9±5.8,4.1±4.3,4.7±5.1; p .726/.944/.880; only minimal at month 3 marked *. PSQI sleep disturbance: recommended 10.1±4.1,9.6±4.2,9.3±4.7,9.3±4.6; minimal 11.0±4.3,10.4±4.6,9.7±4.5,9.4±4.8; p .912/.692/.541; improvement at all points in recommended and at months 3 and 6 in minimal. Roles & Maudsley (no baseline): recommended 3.2±0.8,2.8±0.9,2.9±1.1 at 6 weeks / 3 months / 6 months; minimal 2.9±1.0,2.8±1.0,2.7±1.1; within-arm significance marked *** at all follow-ups in both groups; no interaction p is provided.

Analysis details and source

No time-by-group interaction was significant. Exact scale direction/ranges are described in Table 4 key. No baseline Roles & Maudsley value was reported.

Physical activity1 reported outcome
06
Baseline, 6 weeks, 3 months, and 6 months

Physical activity

IPAQ short-form 7-day recall; Vital Signs activity questions minutes/week or weekday sitting hours

All means ± SD; order baseline / 6 weeks / 3 months / 6 months. IPAQ vigorous minutes/week: recommended 65±285 / 87±334 / 74±337 / 76±288; minimal 61±270 / 69±150 / 134±388 / 137±358; interaction p .839/.456/.413. IPAQ moderate minutes/week: recommended 52±125 / 107±464 / 147±436 / 40±82; minimal 102±309 / 106±245 / 136±286 / 181±410; p .529/.455/.207. IPAQ walking minutes/week: recommended 306±617 / 411±693* / 357±536 / 281±376; minimal 270±427 / 383±565 / 406±529* / 433±720*; p .954/.543/.195. IPAQ weekday sitting hours: recommended 5.3±3.7 / 4.7±3.8 / 5.1±6.4 / 5.3±4.0; minimal 4.7±3.3 / 4.6±3.4 / 4.7±2.1 / 4.2±2.9; p .573/.865/.546. Vital Signs active minutes/week: recommended 141±350 / 150±512 / 144±364 / 92±295; minimal 134±316 / 146±314 / 153±366 / 169±361; p .982/.859/.337. No other within-group significance marks appear.

Analysis details and source

No between-group time interaction for any activity measure. The few within-group improvements in walking do not establish an effect of dose.

Worst pain6 reported outcomes
07
6 weeks

Worst pain

NRS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
6.9
Minimal-dose radial ESWT
5.9
010 points
Worst pain · 6 weeks · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT558 (SD 1.4)6.9 (SD 2.4)
Minimal-dose radial ESWT627.9 (SD 1.6)5.9 (SD 2.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.115. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

08
3 months

Worst pain

NRS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
6.2
Minimal-dose radial ESWT
6
010 points
Worst pain · 3 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT558 (SD 1.4)6.2 (SD 2.5)
Minimal-dose radial ESWT607.9 (SD 1.6)6 (SD 2.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.933. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

09
6 months

Worst pain

NRS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
6
Minimal-dose radial ESWT
5.5
010 points
Worst pain · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT558 (SD 1.4)6 (SD 2.8)
Minimal-dose radial ESWT627.9 (SD 1.6)5.5 (SD 3.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.49. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

10
6 weeks

Average stiffness

NRS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
4.1
Minimal-dose radial ESWT
3.6
010 points
Average stiffness · 6 weeks · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT555 (SD 2.7)4.1 (SD 2.6)
Minimal-dose radial ESWT624.8 (SD 2.8)3.6 (SD 2.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.611. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

11
3 months

Average stiffness

NRS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
3.7
Minimal-dose radial ESWT
3.4
010 points
Average stiffness · 3 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT555 (SD 2.7)3.7 (SD 2.6)
Minimal-dose radial ESWT604.8 (SD 2.8)3.4 (SD 2.5)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.89. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

12
6 months

Average stiffness

NRS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
4
Minimal-dose radial ESWT
3.5
010 points
Average stiffness · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT555 (SD 2.7)4 (SD 2.8)
Minimal-dose radial ESWT624.8 (SD 2.8)3.5 (SD 2.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.621. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

VISA-G3 reported outcomes
13
6 weeks

VISA-G

VISA-G percent

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
53
Minimal-dose radial ESWT
57
0100 percent
VISA-G · 6 weeks · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5545 (SD 18)53 (SD 17)
Minimal-dose radial ESWT6250 (SD 16)57 (SD 19)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.76. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

14
3 months

VISA-G

VISA-G percent

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
55
Minimal-dose radial ESWT
61
0100 percent
VISA-G · 3 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5545 (SD 18)55 (SD 20)
Minimal-dose radial ESWT6050 (SD 16)61 (SD 19)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.94. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

15
6 months

VISA-G

VISA-G percent

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
55
Minimal-dose radial ESWT
62
0100 percent
VISA-G · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5545 (SD 18)55 (SD 22)
Minimal-dose radial ESWT6250 (SD 16)62 (SD 20)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.771. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

Non-Arthritic Hip Score3 reported outcomes
16
6 weeks

Non-Arthritic Hip Score

NAHS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
46.9
Minimal-dose radial ESWT
50.3
080 points
Non-Arthritic Hip Score · 6 weeks · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5543.6 (SD 12.9)46.9 (SD 13.2)
Minimal-dose radial ESWT6242.6 (SD 11.9)50.3 (SD 16.5)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.214. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

17
3 months

Non-Arthritic Hip Score

NAHS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
51.2
Minimal-dose radial ESWT
54.2
080 points
Non-Arthritic Hip Score · 3 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5543.6 (SD 12.9)51.2 (SD 14.2)
Minimal-dose radial ESWT6042.6 (SD 11.9)54.2 (SD 13.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.247. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

18
6 months

Non-Arthritic Hip Score

NAHS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
49.9
Minimal-dose radial ESWT
54.6
080 points
Non-Arthritic Hip Score · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5543.6 (SD 12.9)49.9 (SD 15.4)
Minimal-dose radial ESWT6242.6 (SD 11.9)54.6 (SD 16.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.118. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

Oxford Hip Scale3 reported outcomes
19
6 weeks

Oxford Hip Scale

OHS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
27.9
Minimal-dose radial ESWT
31.1
048 points
Oxford Hip Scale · 6 weeks · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5525.1 (SD 8.1)27.9 (SD 8.8)
Minimal-dose radial ESWT6225.1 (SD 7.9)31.1 (SD 9.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.162. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

20
3 months

Oxford Hip Scale

OHS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
30.8
Minimal-dose radial ESWT
33
048 points
Oxford Hip Scale · 3 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5525.1 (SD 8.1)30.8 (SD 9.1)
Minimal-dose radial ESWT6025.1 (SD 7.9)33 (SD 9)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.336. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

21
6 months

Oxford Hip Scale

OHS points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
29.9
Minimal-dose radial ESWT
34.1
048 points
Oxford Hip Scale · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5525.1 (SD 8.1)29.9 (SD 9.2)
Minimal-dose radial ESWT6225.1 (SD 7.9)34.1 (SD 9.2)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean (SD) values are shown for both groups; the reported time-by-group interaction was p=0.065. The table separately marks within-group change from baseline with asterisks. No treatment-effect estimate or confidence interval was reported.

Analysis details and source

The interaction p-value compares change over time between groups; asterisks indicate within-group tests and do not establish between-group superiority.

painDETECT1 reported outcome
22
6 months

painDETECT

painDETECT score

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
9.8
Minimal-dose radial ESWT
8.7
038 score
painDETECT · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5512.4 (SD 7)9.8 (SD 6.2)
Minimal-dose radial ESWT6210.8 (SD 7.4)8.7 (SD 6.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.771; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

Central Sensitization Inventory1 reported outcome
23
6 months

Central Sensitization Inventory

CSI %

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
28
Minimal-dose radial ESWT
26
0100 %
Central Sensitization Inventory · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5533 (SD 16)28 (SD 17)
Minimal-dose radial ESWT6231 (SD 15)26 (SD 17)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.983; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

Oswestry Disability Index1 reported outcome
24
6 months

Oswestry Disability Index

ODI %

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
32
Minimal-dose radial ESWT
25
0100 %
Oswestry Disability Index · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5539 (SD 17)32 (SD 20)
Minimal-dose radial ESWT6234 (SD 14)25 (SD 17)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.656; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

EQ-5D health1 reported outcome
25
6 months

EQ-5D health

EQ-5D %

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
66
Minimal-dose radial ESWT
75
0100 %
EQ-5D health · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5567 (SD 17)66 (SD 23)
Minimal-dose radial ESWT6270 (SD 17)75 (SD 15)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.187; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

HAD anxiety subscale1 reported outcome
26
6 months

HAD anxiety subscale

HADS-A points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
4.5
Minimal-dose radial ESWT
4.5
021 points
HAD anxiety subscale · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT556.1 (SD 3.8)4.5 (SD 3.8)
Minimal-dose radial ESWT625.4 (SD 3.7)4.5 (SD 4.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.544; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

HAD depression subscale1 reported outcome
27
6 months

HAD depression subscale

HADS-D points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
3.9
Minimal-dose radial ESWT
3.9
021 points
HAD depression subscale · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT555.3 (SD 3.3)3.9 (SD 3.5)
Minimal-dose radial ESWT624.9 (SD 3.7)3.9 (SD 3.6)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.646; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

Pittsburgh Sleep Quality Index1 reported outcome
28
6 months

Pittsburgh Sleep Quality Index

PSQI points

BaselineFollow-up
Recommended/maximally tolerated radial ESWT
9.3
Minimal-dose radial ESWT
9.4
021 points
Pittsburgh Sleep Quality Index · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT5510.1 (SD 4.1)9.3 (SD 4.6)
Minimal-dose radial ESWT6211 (SD 4.3)9.4 (SD 4.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.541; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

IPAQ walking activity1 reported outcome
29
6 months

IPAQ walking activity

IPAQ minutes/week

IPAQ walking activity · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT55306 (SD 617)281 (SD 376)
Minimal-dose radial ESWT62270 (SD 427)433 (SD 720)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.195; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

Vital Signs active minutes1 reported outcome
30
6 months

Vital Signs active minutes

Vital Signs minutes/week

Vital Signs active minutes · 6 months · means
GroupnBaselineFollow-up
Recommended/maximally tolerated radial ESWT55141 (SD 350)92 (SD 295)
Minimal-dose radial ESWT62134 (SD 316)169 (SD 361)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

At 6 months, the reported time-by-group interaction was p=0.337; within-group significance markers are separate. No between-group effect estimate or confidence interval was reported.

Analysis details and source

Mean (SD); interaction p compares longitudinal changes, while asterisks mark within-group comparisons.

How treatment was delivered
Randomization and blinding

Randomization by Sealed Envelope software, 1:1 stated in abstract/methods; CONSORT allocation actually 57/63. Treating nurse both randomized and administered treatment, and alone knew allocation; participants masked by positioning and apparent machine-setting changes; assessment clinicians blinded.

Device and modality

Intelect RPW ESWT machine (DJO Global Chattanooga); radial pressure-wave modality. One practitioner delivered all sessions using a standard protocol.

Recommended-dose schedule

Three sessions once weekly for three weeks; 2,000 shocks/session at 20 Hz; operator set maximal comfortably tolerated pressure. Mean pressures 2.3±0.3, 2.8±0.3, 3.3±0.4 bar in sessions 1–3.

Minimal-dose schedule

Three sessions once weekly for three weeks; 500 shocks/session at 20 Hz and 1.4 bar, lowest practical machine setting.

Target and positioning

The article does not state where the radial ESWT was applied or give a point-by-point targeting protocol; patient positioning was used to keep the device out of the participant's view.

Exercise co-intervention

Both groups were taught a structured home programme: hip/low-back mobility and stretching (aiming for three 30-second sets, three times/day as tolerated), daily progressive concentric/eccentric hip-abductor and external-rotator strengthening, and balance progression. Resume from evening of each session and continue throughout follow-up.

Outcome and analysis schedule

Baseline, 6 weeks, 3 months, 6 months; intention-to-treat; two-way repeated-measures ANOVA for time×group; paired t-tests or Wilcoxon for within-group comparisons; p<.05; no missing-value analysis.

HARMS & TOLERABILITY

Minor bruising was reported by 2 participants in each group (3.5% recommended-dose; 3.2% minimal-dose); it did not prevent treatment. No significant erythema, numbness, increased stiffness, or serious untoward event such as tendon rupture was reported. One recommended-dose participant with marked touch hypersensitivity withdrew after session 1 because of treatment pain.

LIMITS OF THE ANALYSIS

The minimal-dose comparator was not an inert sham, and both groups received home rehabilitation; the study cannot determine whether rESWT adds benefit over exercise/time or whether minimal-dose ESWT itself is therapeutic.

No missing-value analysis was performed; one participant per group withdrew after six weeks, and interim attendance varied. Authors state follow-up ended at six months, so longer-term persistence is unknown.

The abstract and Methods describe equal randomization, but CONSORT Figure 1 reports 57 allocated to intervention and 63 to control. The article does not explain this difference.

The authors consider whether this device or schedule was insufficient, whether more sessions might be needed, and whether the minimal dose itself produced benefit; the study cannot resolve these mechanisms.

Activity measures showed no consistent improvement, and mood/global-health outcomes had fewer or inconsistent within-group changes despite improvements in local symptoms.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • The minimal-dose comparator was not an inert sham, and both groups received home rehabilitation; the study cannot determine whether rESWT adds benefit over exercise/time or whether minimal-dose ESWT itself is therapeutic.
  • No missing-value analysis was performed; one participant per group withdrew after six weeks, and interim attendance varied. Authors state follow-up ended at six months, so longer-term persistence is unknown.
  • The abstract and Methods describe equal randomization, but CONSORT Figure 1 reports 57 allocated to intervention and 63 to control. The article does not explain this difference.
  • The authors consider whether this device or schedule was insufficient, whether more sessions might be needed, and whether the minimal dose itself produced benefit; the study cannot resolve these mechanisms.
  • Activity measures showed no consistent improvement, and mood/global-health outcomes had fewer or inconsistent within-group changes despite improvements in local symptoms.
Research review

Source-linked critical reading

Randomized treatment-schedule comparison

Reading depthMaterial consulted
Technical source record

Complete 34-page author-manuscript PDF read including all article sections, full methods and results, CONSORT flow, Tables 1–5 with every key/footnote, discussion, disclosures, data sharing, patient involvement statement and references. Tables were visually inspected. Repository/PubMed metadata were used to resolve a title variant for the same PMID/DOI.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and masking

A double-blind randomized trial at one UK NHS sports medicine clinic randomized 120 participants; CONSORT reports allocation of 57 to recommended-dose and 63 to minimal-dose, despite the abstract’s statement that allocation was equal. The treating nurse knew assignment; participants were masked using positioning and simulated machine-setting adjustments, while follow-up clinicians were blinded.

Participants

Participants were adults with at least six months of lateral hip pain, reproducible tenderness over the greater trochanter and pain on resisted external rotation or abduction, imaging-confirmed by ultrasound or MRI, and inadequate benefit after a structured rehabilitation programme lasting at least three months. Exclusions included gluteal tendon tears, other pain causes, inability/unwillingness to exercise, steroid injection in the previous three months, and anticoagulation. Mean age 60.6 years; 82% women; mean symptom duration 45.4 months.

Recommended-dose treatment

The intervention used an Intelect RPW machine (DJO Global Chattanooga), radial modality, 2,000 shocks at 20 Hz once weekly for three weeks. Operator-adjusted maximally comfortable pressure averaged 2.3±0.3, 2.8±0.3, and 3.3±0.4 bar in sessions 1–3.

Minimal-dose comparator

The control was not sham or no ESWT: it received three weekly sessions from the same device at 20 Hz, 500 shocks per session and the lowest practical pressure setting of 1.4 bar. Both arms received the same stretching/mobility, daily progressive strengthening and balance home programme, advice and analgesia.

Outcomes and follow-up

The primary outcome was between-group change in average pain (0–10 NRS) from baseline to six months. Questionnaires were collected at baseline, six weeks, three months and six months. Secondary outcomes covered worst pain, stiffness, VISA-G, NAHS, OHS, global health, pain processing, mood, sleep and activity. Tables 3–5 report means±SD, within-group significance marks and time-by-group interaction p-values.

Between-group findings

There was no time-by-group interaction at any follow-up for average pain (p=.959, .686, .841 at 6 weeks, 3 months, 6 months), worst pain (.115, .933, .490), stiffness (.611, .890, .621), VISA-G (.760, .940, .771), NAHS (.214, .247, .118), OHS (.162, .336, .065), or wider-function/sleep/activity measures. At six months the primary outcome was 4.6±2.8 versus 4.0±2.7, p=.841. This does not show equivalence; it shows no detected added benefit of the tested higher-dose schedule over the minimal-dose schedule. Both could be active, rehabilitation/time could explain change, or the modality/dose/session count could be insufficient.

Harms and tolerability

Minor bruising was reported by 2 participants in each group (3.5% recommended-dose; 3.2% minimal-dose); it did not prevent treatment. No significant erythema, numbness, increased stiffness, or serious untoward event such as tendon rupture was reported. One recommended-dose participant with marked touch hypersensitivity withdrew after session 1 because of treatment pain.

Limitations and uncertainty

The authors acknowledge no missing-value analysis, six-month follow-up only, and uncertainty about whether minimal-dose ESWT is active, whether ESWT works for chronic GTPS, whether this device differs, or whether more sessions are needed. The control received treatment rather than sham or exercise alone, so ESWT efficacy itself cannot be isolated. Physical activity did not consistently improve. The CONSORT allocation of 57/63 conflicts with abstract text saying equal randomization.

Applicability

This applies to a secondary-care NHS population with imaging-confirmed chronic GTPS after unsuccessful structured rehabilitation, not necessarily to acute symptoms, tendon tears or people who have not exercised. Both groups continued a detailed home exercise programme. Results compare two radial dose schedules on one device, not focused ESWT or ESWT versus no ESWT.

What stronger research should do

A follow-up trial should include exercise-only and credible sham/minimal-sensation controls to separate device effects from rehabilitation and time, prespecify treatment contrasts and clinically important change, report allocation and adherence transparently, and test dose/session schedules with longer follow-up and complete missing-data sensitivity analyses.

THE ORIGINAL SOURCE

Read the original article.

Three Sessions of Radial Extracorporeal Shockwave Therapy Gives No Additional Benefit Over "Minimal-Dose" Radial Extracorporeal Shockwave Therapy for Patients With Chronic Greater Trochanteric Pain Syndrome: A Double-Blinded, Randomized, Controlled Trial.

Wheeler PC, Dudson C, Calver R, Goodall D, Gregory KM, Singh H, Boyd KT. · Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine · 2022

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →